RxDoctor Payments Data

Ashley Toci, MD

Rheumatology · Charlotte, NCNPI 1790096121

Payments from drug & device makers

$7,258in general payments, 2019–2025

Across 364 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$960
  • Johnson & Johnson$722
  • AstraZeneca$596
  • E.r. Squibb & Sons, L.L.C.$574
  • Novartis$534
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$7,21899%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,258 in reported general payments places this provider in the 60th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,487,281
Medicare patients
646
Services billed
130,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab71$528,932
Enbrel SureclickEtanercept58$422,013
Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty14$213,760
Cosentyx Sensoready (2 Pens)Secukinumab21$188,751
RinvoqUpadacitinib30$187,944
Enbrel MiniEtanercept17$140,202
Xeljanz XrTofacitinib Citrate15$100,732
Taltz AutoinjectorIxekizumab12$87,136
OtezlaApremilast11$75,802
OrenciaAbatacept/Maltose12$71,765
SimponiGolimumab12$70,320
RasuvoMethotrexate/Pf42$29,351
Hydroxychloroquine Sulfate470$16,210
MethotrexateMethotrexate Sodium397$8,563
Leflunomide123$6,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$960$187,94430 claims
AmgenOtezla$1,353$75,80211 claims
E.r. Squibb & Sons, L.L.C.Orencia$574$71,76512 claims
Johnson & JohnsonSimponi$722$70,32012 claims
Scilex Pharmaceuticals Inc.Colchicine$45$1,40339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →